Company profile

Argenx SE

Pipeline12 assets

EfgartigimodVYVGART; VYVGART Hytrulo / FcRn / antibody fragment / Autoimmune
Generalized Myasthenia Gravis (gMG)CommercialChronic Inflammatory Demyelinating Polyneuropathy (CIDP)CommercialPrimary Immune Thrombocytopenia (ITP)CommercialJapan
EmpasiprubartC2 / monoclonal antibody / Autoimmune
Multifocal Motor Neuropathy (MMN)RegistrationalDelayed Graft Function (DGF)Proof of ConceptChronic Inflammatory Demyelinating Polyneuropathy (CIDP)Registrational
AdimanebartMuSK / agonist antibody / Neurology
Congenital Myasthenic Syndromes (CMS)Proof of ConceptSpinal Muscular Atrophy (SMA)Proof of Concept
ARGX-109ARGX-109 / IL-6 / antibody / Undisclosed
UndisclosedPhase 1
ARGX-121ARGX-121 / IgA / antibody / Undisclosed
UndisclosedPhase 1
ARGX-213ARGX-213 / FcRn / antibody / Undisclosed
UndisclosedPhase 1
ARGX-118ARGX-118 / Galectin-10 / Airway Inflammation
Airway InflammationPreclinical
ARGX-125ARGX-125 / bispecific antibody / Undisclosed
UndisclosedPreclinical
TSP-101TSP-101 / Fn14 / Undisclosed
UndisclosedPreclinical
LP0145ARGX-112 / IL-22R / SIMPLE Antibody / Dermatology
Atopic Dermatitispartnered
AGMB-101ARGX-114 / MET / HGF-mimetic agonist antibody
ABBV-151ARGX-115 / GARP-TGF-beta1 / SIMPLE Antibody / Oncology
Tumorspartnered

Latest news20 items

Sep 29, 2026

argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline

New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patients Real-world evidence from more than 1,100 U.S. MG patients indicates the value of treating earlier with VYVGART Long-term data

Presentation / AbstractAANEM/MGFA scientific session presentations Tue, Sep 29, 2026

Sep 17, 2026

argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors

September 17, 2026 – 22:01PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced the results of the Extraordinary General Meeting of Shareholders and appointments of Thomas M. Brakel and Khurem Farooq as non-executive

Sep 1, 2026

argenx to Present at Upcoming Investor Conferences

September 1, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor conferences in September: Wells Fargo 21st Annual Healthcare Conference.

Aug 27, 2026

argenx Completes Acquisition of Forte Biosciences, Inc.

Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx’s immunology pipeline August 27, 2026 – 8:50 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company today announced the successful completion of the acquisition of Forte

Aug 17, 2026

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM First Phase 3 study to show

Trial Results • Phase 3Results event Mon, Aug 17, 2026

Aug 6, 2026

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

August 6, 2026 – 7:45 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company today announced that Avena Merger Sub Inc. (“ Purchaser ”), a wholly-owned subsidiary of argenx BV (“ argenx ”), has commenced a tender offer to purchase all of the

Aug 3, 2026

argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026

August 3, 2026 – 22:01 PM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of Shareholders will

Jul 27, 2026

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline

Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth FB102 Phase 1b studies in vitiligo and celiac disease validate CD122 biology and pipeline-in-a-product potential to address

Jul 23, 2026

argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update

Strong second quarter performance with $1.5 billion in global product net sales, representing 60% year-over-year growth and 17% quarter-over-quarter growth Successfully launched VYVGART and VYVGART Hytrulo in anti-AChR antibody negative (“seronegative”) gMG, expanding patient reach to all gMG

Jul 16, 2026

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

July 16, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 23, 2026 at 2:30

Jun 23, 2026

argenx to Host Autoimmune Myositis R&D Webinar

June 23, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will host a webinar titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis”

Jun 3, 2026

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026

ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in Sjogren’s disease indicate maintenance of response following switch to biweekly dosing Cross-indication analysis of efgartigimod data across rheumatology studies

Presentation / Abstract • Phase 2EULAR 2026 presentation Wed, Jun 3, 2026, 7:00 AM CEST

May 28, 2026

argenx to Host Myositis R&D Webinar on June 23, 2026

May 28, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune

May 27, 2026

argenx to Present at Upcoming Investor Conferences

May 27, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in

May 8, 2026

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative Patients treated with VYVGART in the ADAPT SERON study experienced rapid,

May 7, 2026

argenx Reports First Quarter 2026 Financial Results and Provides Business Update

$1.3 billion in first quarter global product net sales, representing 63% year-over-year growth Anti - AChR antibody negative (“seronegative”) gMG PDUFA is May 10, 2026 Management to host conference call today at 2:30 PM CET ( 8:30 AM ET) May 7, 2026 7:00AM CET Amsterdam, the Netherlands –

May 6, 2026

argenx to Present at BofA Securities 2026 Health Care Conference

May 6, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, Chief Executive Officer, will present at the BofA Securities 2026 Health

May 6, 2026

argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer

Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of people suffering from severe autoimmune diseases, today announced the results of the Annual General

Apr 30, 2026

argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

April 30, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 7, 2026 at 2:30 PM

Apr 18, 2026

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population ADAPT SERON, OCULUS, and Jr study results build on VYVGART's approved gMG indication and show its potential as

Presentation / Abstract • Phase 3